Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00567814 · ClinicalTrials.gov registry record · NA

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

A NA study of Cocaine Dependence and Cocaine Addiction, sponsored by Embera NeuroTherapeutics.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT00567814 is a NA study of Cocaine Dependence and Cocaine Addiction that has completed, run by Embera NeuroTherapeutics. The registered enrollment target is 45 participants, below the 297-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00567814, a NA study of Cocaine Dependence and Cocaine Addiction, has completed, sponsored by Embera NeuroTherapeutics.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be questioned regarding drug craving and mood symptoms.

Interventions

  • DRUG Placebo
  • DRUG Metyrapone
  • DRUG Oxazepam

Study Locations (1)

Louisiana

  • Department of Psychiatry, Psychopharmacology Research Clinic - Shreveport

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2007-12
Est. Completion 2008-11
Phase NA

Sponsor

Embera NeuroTherapeutics

6 total trials

What the Registry Record Tells You About NCT00567814

The ClinicalTrials.gov registry entry for NCT00567814 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 297-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (85% lower). The listed sponsor is Embera NeuroTherapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cocaine Dependence appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00567814 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT00567814 about?

NCT00567814 is a clinical study titled "A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction". Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks. The study will include twice weekly visits to the research clinic for laboratory studies, safety assessments and urine drug screens. Subjects will also be...

What is the current status of trial NCT00567814?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2007-12. Estimated completion is 2008-11.

What conditions does trial NCT00567814 study?

This clinical trial studies the following conditions: Cocaine Dependence, Cocaine Addiction.

What interventions are being tested in trial NCT00567814?

The interventions under investigation include: Placebo (DRUG), Metyrapone (DRUG), Oxazepam (DRUG).

Who is sponsoring clinical trial NCT00567814?

This trial is sponsored by Embera NeuroTherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00567814 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.